Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial
Christopher Maximilian Arends, Savvina Dimitriou, Arndt Stahler, Raphael Hablesreiter, Paulina M. Strzelecka, Catarina M. Stein, Marlon Tilgner, Ryunosuke Saiki, Seishi Ogawa, Lars Bullinger, Dominik Paul Modest, Sebastian Stintzing, Volker Heinemann, Frédérik Damm
Abstract
Clonal hematopoiesis (CH), defined by the acquisition of somatic mutations in hematopoietic stem cells, occurs in 20% to 30% of individuals .60 years and most frequently affects epigenetic regulator genes (DNMT3A, TET2, and ASXL1). CH is associated with a higher overall mortality and an approximately 10-fold risk for the development of hematologic malignancies. Reduced overall survival (OS) in individuals with CH is mainly caused by an increased rate of cardiovascular events. 2,3 4]